stockportfolio.pro
Stocks / SGMT vs UPB
SGMT vs UPB
Sagimet Biosciences Inc. and Upstream Bio, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Sagimet Biosciences Inc. (SGMT) | Upstream Bio, Inc. (UPB) | |
|---|---|---|
| Market cap | $0.4B | $0.3B |
| Revenue (latest FY) | $0 | $2.85M |
| Net income (latest FY) | $-51.04M | $-143.44M |
| Revenue growth (5y CAGR) | — | 33.0% |
| Net margin | — | -5026.0% |
| Return on equity | -45.8% | -42.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open SGMT — free Open UPB — freeFrequently asked questions
Which is bigger, SGMT or UPB?
Sagimet Biosciences Inc. is larger by market capitalization — $0.4B versus $0.3B.
Which grows faster, SGMT or UPB?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.